Ensign vs National HealthCare
ENSG and NHC side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ENSG and NHC compare
Ensign is the larger company, worth 3.4 times as much as National HealthCare ($10.9B against $3.2B).
On earnings, National HealthCare is cheaper: it trades at 23.2× trailing earnings, against 29.2× for Ensign.
Ensign grew revenue faster over the last twelve months (18.9% versus 6.9% for National HealthCare).
National HealthCare keeps more of each dollar of sales as profit, with a net margin of 9.0% compared with 6.9% at Ensign.
Both pay dividends: Ensign yields 0.14% and National HealthCare 1.3%.
National HealthCare scores higher on the StockData Score (21 against 19 for Ensign), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ENSG | NHC |
|---|---|---|
| Size and price | ||
| Market cap | $10.9B | $3.2B |
| Share price | $186.32 | $206.14 |
| Change, 1 year | 0.37% | 70.6% |
| Change, 5 years | 124% | 170% |
| Beta (5Y) | 0.46 | 0.44 |
| Employees | 46K | 15K |
| StockData Score | ||
| Total score | 19 | 21 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 5 (better) | 4 |
| Performance score | 6 (better) | 5 |
| Health score | 5 | 6 (better) |
| Dividend score | 3 | 4 (better) |
| Valuation | ||
| P/E | 29.2× | 23.2× (better) |
| P/S | 2.0× (better) | 2.1× |
| P/B | 4.4× | 2.9× (better) |
| EV/EBITDA | 18.4× | 16.8× (better) |
| P/FCF | – | 22.0× |
| PEG | 2.10 | 0.31 (better) |
| FCF yield | – | 4.5% |
| Fair value | $151.76 | $170.67 |
| Margin of safety | −22.8% | −20.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 18.9% (better) | 6.9% |
| Revenue growth, 5Y average | 16.1% (better) | 8.1% |
| Net income growth (TTM) | 17.3% | 33.8% (better) |
| EPS growth (TTM) | 15.8% | 32.5% (better) |
| EPS growth, 5Y average | 13.8% | 23.0% (better) |
| Profitability | ||
| Gross margin | 20.7% | – |
| Operating margin | 8.5% | 9.3% (better) |
| Net margin | 6.9% | 9.0% (better) |
| FCF margin | – | 9.4% |
| Return on equity | 17.0% (better) | 13.1% |
| Return on invested capital | 17.7% (better) | 10.6% |
| Financial health | ||
| Debt / equity | 0.06 (better) | 0.00 |
| Net debt / EBITDA | −0.31 | −0.21 |
| Interest coverage | 60.0× (better) | 56.6× |
| Current ratio | 1.21 | 1.86 (better) |
| Altman Z-score | 3.71 | 7.03 (better) |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Dividend yield | 0.14% | 1.3% (better) |
| Payout ratio | 3.9% | 28.4% |
| Years of dividend growth | 15 (better) | 12 |
| Dividend growth, 5Y average | 4.5% (better) | 4.0% |
| Buyback yield | 0.37% (better) | 0.15% |
| Shareholder yield | 0.51% | 1.4% (better) |
| Ownership | ||
| Held by institutions | 90.6% | 65.3% |
| Held by insiders | 3.6% | 9.3% |
| Insider net buying, 12 months | −$13.6M | −$11.0M (better) |
| Short interest, % of float | 2.6% | 5.8% |
Go deeper
- ENSG stock overview
- ENSG income statement
- ENSG valuation and score
- NHC stock overview
- NHC income statement
- NHC valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.